(2013) HER2-positive recurrent breast cancer and metastases of breast cancer, including life-threatening metastases to the brain and dura mater: a case effectively treated with lapatinib plus capecitabine before whole brain radiotherapy. International Cancer Conference Journal 2 , 9-13 /...
"The introduction of anti-HER2 therapies has brought a hugesurvival benefitin early and advanced HER2 positive breast cancer, thus there is now a need for reducing the intensity and side effects of thetreatmentadministered," said Criscitiello. "However, the priority is to identify whichpatientsmig...
In terms of tumor biology, that is where sometimes we do have unique situations where potentially that patient has a HER2-positive breast cancer in 1 breast and a triple-negative breast cancer in the other breast, or within the same breast, 2 components regarding tumor heterogeneity. In those ...
HER2 has been clinically validated as a prominent therapeutic target in breast cancer, and an abundance of data from clinical trials proving the efficacy of trastuzumab, a humanized anti-HER2 monoclonal antibody, has changed the natural history of this disease. Despite positive results from many ...
Trastuzumab deruxtecan is an antibody–drug conjugate with high extracranial activity in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. We conducted the prospective, open-label, single-arm, phase 2 TUXEDO-1 trial. We enrolled patients aged ≥18 years with HER2...
Another Targeted Therapy for ERBB2-Positive Breast Cancer. Voelker R. The FDA recently granted accelerated approval to an antibody-drug combination for adults who've already received at least 2 treatment regimens for unresectable or metastatic breast cancer that is positive for human epidermal growth...
first 3 months, and then every 3 months as needed during treatment with NERLYNX. Your healthcare provider will stop your treatment with NERLYNX if your liver tests show severe problems. Call your healthcare provider right away if you get any of the following signs or symptoms of liver ...
(P) combined with 4 cycles of epirubicin and cyclophosphamide followed by 4 cycles of taxane and trastuzumab (P + EC-TH) regimen as neoadjuvant therapy for human epidermal growth factor receptor 2 (HER2) positive breast cancer and to investigate the predictive value of p53, p63, and ...
metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. About MARGENZA MARGENZA is an infusion that was approved by the US Food and Drug Administration (FDA) in 2020. ...
Breast Cancer: Targets and Therapy Dovepress open access to scientific and medical research Open Access Full Text Article Trastuzumab emtansine in the treatment of HER2-positive metastatic breast cancer in Japanese patients Review This article was published in the following Dove Press journal: Breast ...